ReviewJournal of gastroenterology2012
Timeline for development of autologous bone marrow infusion (ABMi) therapy and perspective for future stem cell therapy.
Review in Journal of gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Enhancing mesenchymal stem cell survival and homing capability to improve cell engraftment efficacy for liver diseases.Stem cell research & therapy · 2023Review
- Potential advantages of genetically modified mesenchymal stem cells in the treatment of acute and chronic liver diseases.Stem cell research & therapy · 2023Review
- Clinical Trials of Stem Cell Therapy in Japan: The Decade of Progress under the National Program.Journal of clinical medicine · 2022Review
- Transition of clinical and basic studies on liver cirrhosis treatment using cells to seek the best treatment.Inflammation and regeneration · 2021Review
- Role of the Microenvironment in Mesenchymal Stem Cell-Based Strategies for Treating Human Liver Diseases.Stem cells international · 2021Review
- The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future.Clinical and molecular hepatology · 2021Review
- CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGFβ-induced HSC-T6 cells activation.International journal of nanomedicine · 2019Article
- [Effect of adipose tissue-derived mesenchymal stem cell transplantation in treatment of liver fibrosis and possible mechanism].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2018Article
- Current Perspectives Regarding Stem Cell-Based Therapy for Liver Cirrhosis.Canadian journal of gastroenterology & hepatology · 2018Review
- Effects of Fibrotic Tissue on Liver-targeted Hydrodynamic Gene Delivery.Molecular therapy. Nucleic acids · 2016Article
- Effective Prevention of Liver Fibrosis by Liver-targeted Hydrodynamic Gene Delivery of Matrix Metalloproteinase-13 in a Rat Liver Fibrosis Model.Molecular therapy. Nucleic acids · 2016Article
- Mesenchymal stem cell therapy for cirrhosis: Present and future perspectives.World journal of gastroenterology · 2015Review
- Bone marrow stem-cell therapy for genetic and chronic liver diseases.Hepatology international · 2014Article
- Bone marrow cell-based regenerative therapy for liver cirrhosis.World journal of methodology · 2013Review
- Bringing back the help: autologous bone marrow infusion restores CD4+ T cells in AIDS patients with chronic liver disease.Cell death & disease · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver cirrhosis patients generally progress to liver failure. To cure this progressive disease, we developed a novel cell therapy using bone marrow cells; autologous bone marrow cell infusion (ABMi) therapy. We previously described the possible action mechanism of ABMi therapy in the cirrhotic liver, and showed the timeline and results of clinical studies of ABMi therapy. We have also carried out other clinical studies using bone marrow cells and granulocyte colony-stimulating factor. Here, we report a new randomized clinical trial to evaluate the effects of ABMi therapy. However, ABMi therapy may not be possible in patients who are unable to undergo general anesthesia; therefore, we have started to develop a next-generation stem cell therapy using cultured mesenchymal stem cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.